Table 1 Anti-HIV and HCV mAbs in clinical development.
From: Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
Compound | Target | Origin | Company | Indication | |
|---|---|---|---|---|---|
MAbs against viral antigens | |||||
3 mAb cocktail C2F5, C2G12, and C4E10 | Anti-Gp41, anti-glycan structure of Gp120 | Human mAb | Rockefeller University | Therapy of HIV infection Phase I/II | |
P2G12 | Anti-glycan structure of Gp120 | Human mAb | University of Surrey European Commission | Prevention of HIV infection Phase I | |
KD-247 | Anti-V3 loop of HIV-1 Env | Humanized mAb | The Chemo-Sero-Therapeutic Research Institute | Therapy of HIV infection Phase I | |
F105 | Anti-Gp120, CD4 binding site | Human mAb | National Institute of Allergy and Infectious Diseases (NIAID) | Therapy of HIV infection Phase I | |
MBL-HCV1 | Anti-E2 | Human mAb | MassBiologics | Prevention of liver reinfection with HCV after transplantation Phase II | |
MAbs against host antigens | |||||
IBALIZUMAB | Anti-CD4 receptor | Humanized mAb | TaiMed Biologics/Tanox | Therapy of HIV infection Phase I/II | |
PRO-140 | Anti-CCR5 receptor | Humanized mAb | Progenics/PDL | Therapy of HIV infection Phase I/II | |
CCR5mAb004 | Anti-CCR5 receptor | Human mAb | Human Genome Sciences | Therapy of HIV infection Phase I | |
BAVITUXIMAB | Anti-phosphatidyl serine. | Chimeric mAb | Peregrine Pharmaceuticals | Therapy of HIV/HCV co-infection Phase II | Therapy of chronic HCV infection co-administrated with ribavirin Phase II |
Immunomodulatory mAbs | |||||
TREMELIMUMAB CP 675,206 | Anti-CTLA-4 | Humanized mAb | Pfizer | Therapy of HIV infection Phase I (study withdrawn prior to enrollment) | Therapy of advanced HCC in HCV infected patient Phase II |
CT-011 | Anti-PD-1 | Humanized mAb | CureTech | Therapy of chronic HCV infection Phase I/II | |
BMS 936558 (MDX1106) | Anti-PD-1 | Human mAb | Bristol-Myers Squibb/Medarex | Therapy of chronic HCV infection Phase I | |